Cardiac Amyloidosis Treated with an Implantable Cardioverter Defibrillator and Subcutaneous Array Lead System: Report of a Case and Literature Review
Key result
ICD with a subcutaneous array lowers DFT in a patient with cardiac amyloidosis.
- n=1
Why the study?
Preventing ventricular arrhythmias in cardiac amyloidosis patients is challenging due to amyloid infiltration affecting cardiac electrical excitation and elevated defibrillation thresholds.
Does an implantable cardioverter defibrillator with a subcutaneous array lead system reduce defibrillation threshold in a patient with cardiac amyloidosis?
Population
64-year-old female with cardiac amyloidosis
Comparison
ICD with subcutaneous array lead system vs standard ICD implantation strategies
Design
Case report
Authors
Discussion
Loading...
Member takes
Implication
May warrant consideration for high defibrillation thresholds in cardiac amyloidosis; hypothesis-generating and requires prospective validation.
Study Design
Type
Case Report (n=1)
Structured PICO
Does an implantable cardioverter defibrillator with a subcutaneous array lead system reduce defibrillation threshold in a patient with cardiac amyloidosis?
P
Population
A 64-year-old female with cardiac amyloidosis treated with an ICD and a subcutaneous array lead system.
I
Intervention
Implantable cardioverter defibrillator (ICD) and a subcutaneous array lead system
O
Outcome
Reduction of defibrillation threshold (DFT) and termination of ventricular tachycardia or fibrillation
In patients with cardiac amyloidosis who have elevated defibrillation thresholds, a subcutaneous array lead system can be a successful strategy to ensure effective ICD therapy.
Cite This Study
Dhoble et al. (2009) conducted a case report in Cardiac amyloidosis (n=1). Implantable cardioverter defibrillator (ICD) and subcutaneous array lead system was evaluated on Defibrillation threshold (DFT) reduction and termination of ventricular tachycardia or fibrillation. An implantable cardioverter defibrillator with a subcutaneous array lead system successfully reduced the defibrillation threshold in a patient with cardiac amyloidosis.